Finding could lead to reduced side effects in anti-cancer antibiotics

June 28, 2011 in Cancer

Most of us have had a doctor prescribe an antibiotic for a stubborn bacterial infection, or for a cut that gets infected. However, prescribing an antibiotic to fight cancer? In fact, anti-cancer antibiotics have been used since the 1950s to successfully treat several forms of cancer, but often the side effects limit the duration they can be given to a patient.

One particularly promising anti-cancer antibiotic is Geldanamycin and a modified form of this drug known as 17AAG. Despite its proven ability to selectively kill many different forms of cancer in laboratory studies, the use of these drugs is limited due to side effects, mainly , in patients.

Newly published results from Van Andel Research Institute (VARI) researchers have determined how the anti-cancer antibiotic Geldanamycin and its derivative 17AAG work in more detail and have uncovered a possible explanation for side effects observed in clinical trials of the drug.

"The article provides novel and significant information about the clinical potential of these compounds in ," said Yale School of Medicine Professor and Chair of Pharmacology Joseph Schlessinger, Ph.D.

Although there was much preclinical interest in the antibiotic Geldanamycin as an anti-cancer drug, it turned out to be a poor candidate for clinical trials because of its toxicity. Derivatives such as 17AAG were developed to decrease toxicity and are still being evaluated in clinical trials.

VARI researchers determined how Geldanamycin and 17AAG work in more detail in a study published in U.S.A., which could inform future drug design, and also found a way to potentially decrease the antibiotics' toxicity.

"There was so much interest early on in Geldanamycin because it resulted in the degradation of oncoproteins, important protein targets in ," said VARI Research Scientist and lead author of the paper Qian Xie, M.D., Ph.D.

"If there is a chance of decreasing the toxicity of Geldanamycin and 17AAG, it would be a boon in the treatment of cancer," said George Vande Woude, Ph.D., head of the Laboratory of Molecular Oncology at VARI that published the study.

Provided by Van Andel Research Institute

5 /5 (1 vote)  

Rank 5 /5 (1 vote)
Relevant PhysicsForums posts
  • For Sale virormone testosterone:$6
    created1 hour ago
  • A question about drug tolerance
    createdMay 23, 2012
  • Poor nutrition leading to overeating?
    createdMay 23, 2012
  • Math and dyslexia?
    createdMay 21, 2012
  • portable metabolism meter?
    createdMay 21, 2012
  • Rare medical conditions on 20/20 tonight
    createdMay 18, 2012
  • More from Physics Forums - Medical Sciences

More news stories

Brentuximab vedotin effective in large-cell lymphoma

(HealthDay) -- More than half of patients with relapsed or refractory systemic anaplastic large-cell lymphoma (ALCL) treated with the CD30-directed antibody-drug conjugate brentuximab vedotin achieve a complete ...

Cancer created 10 hours ago | popularity not rated yet | comments 0

Childhood cancer scars survivors later in life

Scars left behind by childhood cancer treatments are more than skin-deep. The increased risk of disfigurement and persistent hair loss caused by childhood cancer and treatment are associated with emotional distress and reduced ...

Cancer created 13 hours ago | popularity not rated yet | comments 0

Amino acid consumption associated with how fast cancer cells divide

For almost a century, researchers have known that cancer cells have peculiar appetites, devouring glucose in ways that normal cells do not. But glucose uptake may tell only part of cancer's metabolic story. Researchers from ...

Cancer created 13 hours ago | popularity 5 / 5 (4) | comments 1 | with audio podcast

Marked for destruction: Newly developed compound triggers cancer cell death

The BCL-2 protein family plays a large role in determining whether cancer cells survive in response to therapy or undergo a form of cell death known as apoptosis. Cells are pressured toward apoptosis by expression of pro-apoptotic ...

Cancer created 16 hours ago | popularity 5 / 5 (1) | comments 0

Thioridazine kills cancer stem cells in human while avoiding toxic side-effects of conventional cancer treatments

A team of scientists at McMaster University has discovered a drug, thioridazine, successfully kills cancer stem cells in the human while avoiding the toxic side-effects of conventional cancer treatments.

Cancer created 16 hours ago | popularity 4.7 / 5 (26) | comments 2 | with audio podcast


Like curry? New biological role identified for compound used in ancient medicine

Scientists have just identified a new reason why some curry dishes, made with spices humans have used for thousands of years, might be good for you.

'Personality genes' may help account for longevity

"It's in their genes" is a common refrain from scientists when asked about factors that allow centenarians to reach age 100 and beyond. Up until now, research has focused on genetic variations that offer a physiological advantage ...

Gene discovery points towards non-hormonal male contraceptive

A new type of male contraceptive could be created thanks to the discovery of a key gene essential for sperm development.

Cyber exercise partners help you go the distance: Motivation gains can double

A new study testing the benefits of a virtual exercise partner shows the presence of a moderately more capable cycling partner can significantly boost the motivation – by as much as 100 percent – ...

Researchers identify protein necessary for behavioral flexibility

Researchers have identified a protein necessary to maintain behavioral flexibility, which allows us to modify our behaviors to adjust to circumstances that are similar, but not identical, to previous experiences. Their findings, ...

New test shows potential for detecting active cases of Lyme disease

George Mason University researchers can find out if a tick bite means Lyme disease well before the bite victim begins to show symptoms.